Santhera is a Swiss specialty pharmaceuti- cal company focused on the development and commercialization of products for the treatment of mitochondrial and neuromuscular diseases, areas which include many orphan and niche indications with no current therapy. Santhera strategically focuses on the development of Raxone®/Catena® (INN: idebenone).

Santhera has a late-stage development pipeline in orphan indications. The lead compound Raxone®/Catena® (INN: idebenone) is being developed in four indications: Leber's Hereditary Optic Neuropathy, Duchenne Muscular Dystrophy, Primary Progressive Multiple Sclerosis and MELAS syndrome.

Currently, three clinical studies are evaluating the safety and efficacy of Catena®:
- DELOS in Duchenne Muscular Dystrophy
- IPPoMS in Primary Progressive Multiple Sclerosis, conducted by the National Institutes of Health
- MELTIMI in MELAS syndrome, conducted by the Columbia University Medical Center, New York.